Ionis CEO Brett Monia Sells Shares of IONS

Brett Monia, the Chief Executive Officer of Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), sold 14,565 shares of the company on June 24, 2026. This transaction was not part of a pre-arranged trading plan. The shares traded near $78.34 on the Saturday following the sale.

What Changed in Brett Monia's Ionis Pharmaceuticals Position

Brett Monia's sale of 14,565 shares comes amidst various insider trading activities at Ionis Pharmaceuticals. This transaction was not executed under a Rule 10b5-1 trading plan, indicating it was not pre-scheduled.

Other Institutional Activity in Ionis Pharmaceuticals

Several institutional investors have adjusted their holdings in Ionis Pharmaceuticals. FMR LLC increased its stake by 484,536 shares, bringing its total to approximately 24.6 million shares, valued at about $1.84 billion. CAPITAL WORLD INVESTORS added 3,225,070 shares, now holding around 21.2 million shares worth $1.59 billion, marking an 18% increase. BLACKROCK, INC. reduced its position by 205,387 shares, leaving it with 10.4 million shares valued at $784.1 million, a 1.9% decrease. VANGUARD PORTFOLIO MANAGEMENT LLC and VANGUARD CAPITAL MANAGEMENT LLC both opened new positions, holding 7.8 million and 7.1 million shares, respectively, valued at $586.4 million and $534.5 million.

Ionis Pharmaceuticals, Inc. Stock Up 28.3%

Shares of Ionis Pharmaceuticals traded near $78.34 on Saturday. The company has a market capitalization of approximately $12.95 billion. With a forward P/E ratio of -105.33, Ionis is not currently profitable. The stock has experienced a 52-week low of $39.37 and a high of $86.74. Its 50-day moving average is $74.96, while the 200-day moving average is $75.32. Ionis maintains a current ratio of 4.10 and a quick ratio of 2.86, with a debt-to-equity ratio of 531.05.

Recent Earnings

Ionis Pharmaceuticals reported revenues of $1.06 billion, reflecting a growth rate of 0.87%. The company posted a net margin of -30.9% and a return on equity of -67.6%. The next earnings report is anticipated on April 29, 2026.

Insider Buying and Selling at Ionis Pharmaceuticals, Inc.

In addition to Brett Monia's sale, Eric Swayze, EVP of Research, sold 10,602 shares at an average price of $79.18 on June 25, 2026. This transaction was conducted under a Rule 10b5-1 plan.

Analysts Set New Price Targets

On June 25, 2026, Goldman Sachs maintained a 'hold' rating with a $75 price target, while Leerink Partners and HC Wainwright & Co. both upheld 'buy' ratings with targets of $129 and $130, respectively. The consensus among analysts is a 'buy' recommendation, with an average target price of $105.91 based on 23 analyst opinions.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California. The company focuses on developing RNA-targeted therapies for a variety of medical conditions. Ionis offers products like TRYNGOLZA for triglyceride levels, DAWNZERA for hereditary angioedema, and SPINRAZA for spinal muscular atrophy. It also has several products in clinical trials, including treatments for cardiovascular disease and rare genetic disorders. Ionis collaborates with major pharmaceutical companies like Biogen, GSK, and AstraZeneca.

Bottom Line

Brett Monia's recent sale of Ionis Pharmaceuticals shares adds to the ongoing insider trading activity at the company. Investors often monitor such moves as part of their due diligence. Meanwhile, Ionis continues to attract attention from analysts, maintaining a 'buy' consensus despite its current lack of profitability. As always, remember that 13F filings and insider transactions provide a historical view, not necessarily reflecting the current position or sentiment.